Saturday, April 29, 2023, San Antonio, Texas, 12:15 PM – 1:45 PM Central Time (1:15 PM – 2:45 PM Eastern Time)

What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation

Fifteenth Annual RTP Symposium Series Held During the Annual ONS Congress

Prostate Cancer

 
Location
Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Program Schedule — Central Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — Lunch Meeting

Meeting Room
Texas Ballroom (Salons A-C) – Fourth Floor


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Neeraj Agarwal, MD, FASCO
Professor of Medicine
Senior Director for Clinical Research Innovation
Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

Kathy D Burns, RN, MSN, AGACNP-BC, OCN
Genitourinary Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California


Susan K Roethke, MSN, CRNP, AOCNP, ANP-BC
Genitourinary Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Sandy Srinivas, MD
Professor of Oncology
Clinical Research Leader, GU Oncology
Stanford University
Stanford, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, Novartis, and Pfizer Inc during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26–30, 2023 in San Antonio, Texas. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — Educational Lunch Meeting

What I Tell My Patients About ...

Treatment Approaches for Nonmetastatic Prostate Cancer

  • Indications for and selection of androgen deprivation therapy (ADT) for patients with prostate cancer
  • Key findings with the oral LHRH antagonist relugolix in men with advanced prostate cancer; optimal integration opposite standard injectable ADT
  • Published data with the addition of abiraterone and prednisolone with or without enzalutamide to ADT for men with high-risk nonmetastatic prostate cancer
  • Major efficacy and safety results with ADT intensification with apalutamide for patients with biochemically recurrent prostate cancer; ramifications for disease management
  • Research and clinical implications of emerging positive results with enzalutamide alone or combined with leuprolide for men with nonmetastatic hormone-sensitive prostate cancer (HSPC) and high-risk biochemical recurrence
  • Long-term findings with enzalutamide, apalutamide and darolutamide for nonmetastatic castration-resistant prostate cancer (CRPC); factors guiding selection among these agents

The Management of Metastatic HSPC (mHSPC)

  • Rationale for treatment intensification for patients with mHSPC; historical outcomes with ADT alone in this population
  • Long-term data, including overall survival findings, with docetaxel, abiraterone, enzalutamide or apalutamide in combination with ADT for mHSPC
  • Major findings with ADT and docetaxel with or without abiraterone, with or without local radiation therapy for mHSPC
  • Recent FDA approval of darolutamide combined with docetaxel/ADT; selection of appropriate candidates for this strategy

Tolerability of Hormonal Therapy Used in the Treatment of Prostate Cancer

  • Incidence of cardiovascular adverse events among patients with prostate cancer receiving hormonal therapy; appropriate baseline risk assessment, monitoring and management
  • Effect of hormonal therapy on bone health and skeletal-related events in patients with prostate cancer
  • Incidence and management of other notable side effects with hormonal therapy for prostate cancer, such as CNS-related events, hot flashes, sarcopenia and rash

The Current and Future Role of PARP Inhibitors for Metastatic CRPC (mCRPC)

  • Spectrum and frequency of BRCA and other homologous recombination repair (HRR) gene mutations in prostate cancer; indications for and practical implementation of genetic testing
  • FDA-approved indications for olaparib and rucaparib monotherapy for mCRPC and optimal integration into current management algorithms
  • Biologic basis for combining PARP inhibitors with secondary hormonal therapies for prostate cancer
  • Published findings with the combination of olaparib, niraparib and talazoparib, respectively, and androgen receptor-targeted therapy as first-line treatment for patients with mCRPC with and without HRR gene mutations
  • Potential role of PARP inhibitor-based combination strategies for patients with mCRPC with and without HRR mutations

Tolerability and Other Practical Considerations with PARP Inhibitors

  • Incidence, timing and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with mCRPC
  • Tolerability of PARP inhibitors administered in combination with secondary hormonal therapy
  • Optimal monitoring and management of PARP inhibitor-related toxicities
  • Approaches to encourage adherence among patients receiving long-term oral medications, including PARP inhibitors

The Role of Novel Radiopharmaceuticals in the Treatment of mCRPC

  • Patient selection for radium-223 and optimal integration into current mCRPC treatment algorithms
  • Clinical relevance of PSMA expression in prostate cancer; mechanism of action of the novel radioligand therapy lutetium Lu 177 vipivotide tetraxetan
  • Published and emerging data sets with lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mCRPC
  • Optimal integration of lutetium Lu 177 vipivotide tetraxetan into clinical practice
  • Common treatment-emergent adverse events observed with lutetium Lu 177 vipivotide tetraxetan
  • Educating patients receiving radiopharmaceuticals about appropriate radiation protection protocols

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise published research and current guidelines for the management of prostate cancer among patients with biochemical recurrence after local treatment, and counsel appropriate candidates regarding the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC) and metastatic hormone-sensitive prostate cancer (HSPC) and apply this information in the discussion of nonresearch treatment options with patients.
  • Recognize how prior therapeutic exposure and patient and disease characteristics factor into the selection and sequencing of systemic treatments for metastatic CRPC (mCRPC).
  • Assess available research with the use of PARP inhibitors alone or in combination with secondary hormonal therapies for mCRPC, and consider the current and potential role of these agents for patients with and without homologous recombination repair gene mutations.
  • Appreciate available and emerging clinical research documenting the efficacy of PSMA-targeted radioligand therapy for patients with PSMA-positive mCRPC, and consider the current and future clinical role of this strategy.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. https://www.researchtopractice.com/Meetings/ONS2023/Prostate/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Burns and Ms Roethke have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Agarwal — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Janssen Biotech Inc, Lilly, Lumos Pharma, Medivation Inc, a Pfizer Company, Merck, Nektar, Novartis, Pfizer Inc, Prometheus Laboratories Inc, Rexahn Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, Takeda Pharmaceuticals USA Inc, TRACON Pharmaceuticals Inc. Dr Srinivas — Advisory Committee and Consulting Agreements: Janssen Biotech Inc, Merck, Novartis, Seagen Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Exelixis Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, Novartis, and Pfizer Inc.

Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Meeting Room:
Texas Ballroom (Salons A-C) – Fourth Floor

The Grand Hyatt San Antonio is the headquarters hotel for the 2023 ONS Congress and is conveniently connected to the Henry B González Convention Center.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

​ ​ ​
IN-PERSON registration
Thank you for your interest in our NCPD program taking place in San Antonio, Texas. At this time online preregistration for in-person is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 11:45 AM Central Time on Saturday, April 29th. If you are interested in attending, please visit our registration desk located outside the Texas Ballroom (Salons A-C) – Fourth Floor of the Grand Hyatt San Antonio River Walk hotel which is connected to the Henry B Gonzalez Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com.

Please note, onsite registration does not guarantee seating and participation in meal service and will be based on availability.

LIVE WEBCAST registration open to all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.